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High vascular density is associated with a poor prognosis in
muscle invasive bladder cancer (Dickinson et al, 1994; Bochner et
al, 1995; Jaeger et al, 1995). The endothelial specific angiogenic
factor, vascular endothelial growth factor (VEGF) is strongly
implicated as a factor mediating this process with high VEGF
expression related to a poor prognosis in a range of tumours
including superficial bladder cancer (Crew et al, 1997). We previ-
ously demonstrated differential regulation of VEGF mRNA in
bladder cancer with expression higher in superficial compared to
muscle invasive tumours (O’Brien et al, 1995). Little is known
regarding VEGF protein levels in these tumours although several
mechanisms are involved in regulation of the VEGF gene,
including a post-transcriptional component (Ferrara and Davis-
Smyth, 1997). The eukaryotic initiation factor-4E (eIF-4E) is
involved in the translational regulation of VEGF through
increasing the efficiency with which the ribosome binds to mRNA
(Rhoads, 1993; Kevil et al, 1996; Scott et al, 1997). The 7-methyl
guanosine cap of mRNA is recognized by a cap-binding complex
allowing unwinding of the 5¢ untranslated region of the mRNA
regulating attachment of the 40s ribosome and thereby facilitating
translation. This process is the rate-limiting step in protein
synthesis under normal conditions (Marcus, 1970; Darnbrough et
al, 1973). The proto-oncogene eIF-4E is the least abundant factor
within this complex and is itself rate-limiting for protein synthesis.
In addition, eIF-4E can regulate cell growth (Jones et al, 1996),
induce malignant transformation in cell lines (De Benedetti and
Rhoads, 1990) and high expression has been demonstrated in
tumours suggesting a role in tumour biology (Li et al, 1997;
Nathan et al, 1997). Increased eIF-4E expression induces produc-
tion of only a relatively small number of proteins (Rhoads, 1993).
However, the poor prognosis associated with its high expression
within a tumour may partly reflect regulation of factors involved
in angiogenesis including VEGF (De Benedetti & Rhoads, 1990;
Kevil et al, 1995; 1996).
The aim of this study was to quantify VEGF mRNA and protein
in normal bladder and bladder cancers to determine their ratios in
normal and neoplastic tissues. In addition, eIF-4E mRNA expres-
sion was quantified within the same cohort of tumours and corre-
lated with the VEGF expression to establish its role in the
regulation of VEGF in bladder cancer.
MATERIALS AND METHODS
Patients and sample collection
Primary transitional cell carcinomas of the bladder were obtained
from 57 patients undergoing transurethral bladder cancer resection
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Oxford, Oxford OX3 9DU, UKat The Churchill Hospital, Oxford, UK. Twelve specimens of
macroscopically normal bladder were obtained from patients
undergoing surgery for bladder cancer (n = 5) or from cadaveric
organ donors at the time of donor nephroureterectomy (n = 7).
All specimens were snap-frozen in liquid nitrogen at the time of
resection.
RNA and protein preparation
RNA was prepared according to the method of Chomczynski and
Saachi (Chomczynski and Saachi, 1987). All RNA samples were
run on a 1% agarose gel (under RNAase-free conditions) and the
concentrations measured spectrophotometrically prior to ribo-
nuclease protection analysis.
Tumour protein cytosolic and membrane fractions were
prepared as previously described (Sacks et al, 1993). Briefly,
tumours, frozen in liquid nitrogen, were morselized (cooled with
liquid nitrogen) prior to homogenization, using a Dounce homoge-
nizer, in 4 ml of HEPES–EDTA buffer containing proteinase
inhibitors. This homogenate was centrifuged at 3000 g for 10 min
(+4°C) and the supernatant further centrifuged at 100 000 g for
45 min (+2°C). The pellet was resuspended in 1 ml Tris-buffered
saline (TBS) to form the ‘membrane’ fraction whilst the super-
natant formed the ‘cytosol’ fraction. Total protein was quantified
in all fractions using the Bradford method (Bradford, 1976).
Ribonuclease protection assay
Two radiolabelled riboprobes were used to quantify VEGF and
eIF-4E mRNA using ribonuclease protection. Plasmid pBluescript
KS+ containing the full-length of VEGF was linearized with
EcoRV and a 520-nucleotide antisense fragment was generated
with T7 polymerase. Plasmid pGem-7Z containing the full-length
of eIF-4E was linearized using ACC 1 and a 771 nucleotide anti-
sense fragment generated with SP6 polymerase as previously
described (De Benedetti et al, 1991).
The protected fragments for VEGF appeared as a doublet with
the upper band (477 bp) corresponded to the VEGF 121 isoform
whilst the lower band (427 bp) corresponded to the combined
activity of the VEGF 165 and 189 isoforms. For the analysis the
activity in both bands was summed (Crew et al, 1997).
In all protection assays an external control was used. This was
formed from the hybridization of a sense and antisense riboprobe
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
previously described (Scott et al, 1997). Briefly, antisense and
sense GAPDH riboprobes were generated (after linearizing the
pBluescript KS+/GAPDH construct with HindIII and BamH1
respectively) using T3 and T7 polymerase respectively.
Antisense riboprobes, labelled with [32P]dCTP were hybridized
to 10 mg of total cellular RNA, and the free unhybridized probe
was digested with RNAase and T1. Following electrophoresis in a
6% polyacrylamide/urea-sequencing gel the protected fragments
(Figure 1) were analysed using the ImageQuant, Phosphorimager
(Version 3.3, Molecular Dynamics Inc., Sunnyvale, CA, USA).
Analysis was performed in a blinded fashion prior to determining
patient outcome.
To control against losses during the assay signals were normal-
ized to the external control formed by hybridization of the sense
and antisense GAPDH riboprobes (Crew et al, 1997). In addition,
to allow accurate comparisons between ribonuclease protection
assays a positive control was run on all electrophoresis gels. The
positive control was given the value of 100 arbitrary mRNA units
and all other signals were expressed relative to this. A breast
cancer specimen known to express large quantities of eIF-4E
mRNA was used as the positive control for eIF-4E (Scott et al,
1997) whilst a bladder cancer specimen known to express large
quantities of VEGF mRNA was used as the positive control for
VEGF (Crew et al, 1997).
Enzyme-linked immunosorbent assay
The Quantikine™ enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Abingdon, UK) was used to measure VEGF
protein. Both membrane and cytosolic fractions were quantified in
order to ascertain the site of VEGF protein and to determine
whether extracellular sequestration and membrane binding of
VEGF were significant. Fifty micrograms of total protein were
assayed from each sample and the results expressed as ng VEGF
mg–1 total protein.
Prior to the study the ELISA was validated for use with tumour
protein preparations. This was achieved by ensuring that the
buffers used in the protein preparation did not interfere with the
ELISA, and that VEGF retrieval from the preparations remained
linear and parallel to the standard reference curve used in the
ELISA.
Statistics
All statistics were performed using Statview 4.5 (Abacus
Concepts, Berkeley, CA, USA) or Stata 5.0 (Stata Corp, TX,
USA).
RESULTS
VEGF protein expression in bladder cancer and normal
bladder
The subcellular localization of VEGF protein expression within
normal bladder (n = 19) and bladder cancer (n = 42, 26 superficial,
16 muscle invasive) was quantified in cytosolic and membrane
fractions using an ELISA. There was no statistical difference
between the concentration of VEGF in cytosolic or membrane
fractions in any group (normal bladder P = 0.68, superficial
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Figure 1 A representative autoradiograph, following ribonuclease protection
assay, illustrating high eIF-4E mRNA expression in muscle invasive
transitional cell carcinomas of the bladder (n = 4) compared to superficial
transitional cell carcinomas of the bladder (n = 4) or normal bladder samples
(cadaveric organ donors, n = 4). Expression was quantified using
phosphorimager analysis and normalized to positive and external controlsbladder cancer P = 0.40, invasive bladder cancer P = 0.07,
Mann–Whitney U-test) although median VEGF expression was
greater within the cytosolic compartment in all groups (Table 1).
Since reconstitution of the cytosolic fraction was in a volume of
4 ml of buffer compared to only 1 ml for the membrane fraction
the total VEGF protein content within the cytosolic compartment
was greater than in the membrane compartment (P < 0.01 in all
groups). For the remaining analysis VEGF concentrations within
the cytosolic fraction were used.
VEGF mRNA and protein expression
RNA and protein preparations were quantified in 12 specimens of
normal bladder and 57 bladder cancers (39 superficial tumours,
18 muscle invasive tumours). VEGF mRNA varied over 100-fold
across the tumours. VEGF mRNA in both superficial tumours
(median = 100, range 6–345, P < 0.0001 Mann–Whitney U-test)
and muscle invasive tumours (median = 30, range 7–67, P = 0.06)
were higher than in normal bladder (median = 9.5, range 1–78)
(Table 2). In addition, levels were threefold higher in superficial
tumours (median = 100 [standardized to the positive control],
range 6–345) compared to muscle invasive tumours (median = 30,
range 2–70, P = 0.0001).
eIF-4E and VEGF in bladder cancer 163
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Table 1 Subcellular localization of VEGF protein in normal bladder and
bladder cancer
VEGF protein concentration
(pg mg–1 total protein)
Tissue fraction Normal bladder Bladder cancer
median (range) median (range)
Cytosolic 42 (0–404) 1643 (30–4902)
Membrane 32 (0–238) 1299 (128–6006)
Table 2 Median and range of expression of VEGF mRNA, cytosolic protein and protein:mRNA ratios together with the correlating eIF-4E mRNA expression in
normal bladder, superficial and muscle invasive bladder cancer
VEGF mRNA VEGF protein VEGF protein:mRNA EIF-4E mRNA
(arbitrary mRNA units) (pg mg–1 total protein) (pg mg–1 total protein/ (arbitrary mRNA units)
arbitrary mRNA unit)
Median (range) P Median (range) P Median (range) P Median (range) P
n = n = n = n =
Normal bladder 9.5 (1–78) 36 (1–326) 4.0 (0.2–5.9) 5 (2–15)
12 12 12 12 ]
0.0004 ] 
<0.0001 ] 
<0.0001 ] 
<0.0001
Bladder cancer 57 (6–345) 1477 (42–5000) 21.1 (0.8–228.4) 23 (1–144)
57 57 57 53
Superficial bladder 100 (6–345) 1478 (42–5000) 14.2 (0.8–140.8) 19 (1–100)
cancer 39 39 39 37 ]
0.0001 ]  
0.81 ] 
<0.0001 ]  
0.005
Muscle invasive 30 (7–67) 1454 (48–4522) 68.6 (17–228.4) 44 (12–144)
bladder cancer 18 18 18 16
Figure 2 EIF-4E mRNA expression derived from ribonuclease protection assay in normal bladder, superficial and muscle invasive bladder tumours. The
figures represent expression relative to a positive control given the arbitrary value of 100 mRNA units. Median values are illustrated (bars) and P-values were
generated using the Mann–Whitney U-test
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mRNA units)Levels of VEGF cytosolic protein varied over 100-fold across
the tumours. There was no difference between VEGF protein
levels in superficial (median = 1478 pg mg–1 total protein, range
42–5000) or muscle invasive tumours (median = 1454, range
48–4522, P = 0.81), although expression in both phenotypes was
40-fold greater than in normal bladder (median = 36, range 1–326,
P < 0.0001) (Table 2).
The relationship between VEGF mRNA and protein
expression
VEGF mRNA and protein expression correlated in both the
normal bladder (n = 12, r = 0.68, P = 0.02) and bladder cancer
(n = 57, r = 0.46, P = 0.0007). This correlation was more signifi-
cant in superficial (n = 39, r = 0.58, P = 0.0003) compared to
muscle invasive tumours (n = 18, r = 0.48, P = 0.05). Median
VEGF protein:mRNA ratios was fivefold greater in the tumours
compared to normal bladder (P < 0.0001, Mann–Whitney U-test)
indicating that more VEGF protein was generated per unit of
mRNA in bladder cancer compared to normal bladder (Table 2). In
invasive tumours low VEGF mRNA and high protein expression
resulted in VEGF protein:mRNA ratios (median = 68.6, range
17–228.4) fivefold greater than in superficial tumours (median =
14.1, range 0.8–140.8, P < 0.0001) (Table 2). These findings
suggested that in these tumours VEGF was regulated by post-
transcriptional mechanisms.
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Figure 3 The correlation between eIF-4E mRNA expression and VEGF protein:mRNA ratios in normal bladder (n = 8, r = 0.88, P = 0.02, Spearmann’s rank
correlation), superficial and muscle invasive bladder cancer (n = 35, r = 0.36, P = 0.03). Both axes are on logarithmic scales.
EIF-4E and VEGF mRNA are expressed as arbitrary mRNA units generated by normalization to a positive control as described in the text
Figure 4 Kaplan–Meier survival curves illustrating stage progression-free survival (A) and relapse-free survival (B) in 32 T1G1 and T1G2 bladder cancers
expressing high eIF-4E mRNA (n = 16 above the median) and low eIF-4E mRNA (n = 16 below the median). Time to stage progression was shorter in tumours
expressing high eIF-4E mRNA (P = 0.04, Cox proportional hazards model). No difference was demonstrated in time to relapse
(P = 0.08), although levels were higher in tumours recurring by 6 months (P = 0.01, c2 test)EIF-4E in translational regulation of VEGF in bladder
cancer
Expression of eIF-4E mRNA was quantified in 12 normal bladder
samples, 37 superficial (three stage Ta, 34 stage T1) and 16 muscle
invasive bladder tumours using ribonuclease protection analysis.
Expression was lower in normal bladder samples compared to
bladder cancers (P < 0.0001, Mann–Whitney U-test) (Table 2).
Figure 1 is a representative autoradiograph following ribonuclease
protection illustrating the increased in eIF-4E mRNA expression
in malignant compared to non-malignant bladder (Figure 1).
Quantification of this signal following ribonuclease protection was
achieved using phosphorimager analysis as described above. In
bladder cancers there was a 144-fold variation in expression with
levels higher in muscle-invasive compared to superficial tumours
(P = 0.005, Mann–Whitney U-test) (Figure 2). The increase in
eIF-4E mRNA expression correlated with increasing VEGF
protein:mRNA ratios (n = 43, r = 0.54, P = 0.0004) (Figure 3).
This correlation was present in both the normal bladder (n = 8,
r = 0.88, P = 0.02) and bladder cancer (n = 35, r = 0.36, P = 0.03)
indicating an association between the two factors, with eIF-4E
involved in the regulation of VEGF translation in these tumours.
Poorly differentiated (G3) stage T1 tumour carry a poor prog-
nosis with a high risk of stage progression. In this group of
tumours (n = 4, median = 71, range 35–100) eIF-4E mRNA
expression was significantly higher than in well (G1) or moder-
ately (G2) differentiated T1 bladder tumours (n = 32, median = 18,
range 1–78, P = 0.01). In T1G1 and T1G2 tumours (n = 32) eIF-4E
expression above the median was associated, in univariate
analysis, with reduced stage progression-free survival (P = 0.04,
Cox proportional hazards model) (Figure 4) and an increased risk
of recurrence by 6 months (P = 0.01, c2 test) demonstrating that
eIF-4E is a prognostic factor in these tumours. There was an
association with survival in muscle invasive tumours (P = 0.15,
Cox proportional hazards model).
DISCUSSION
It is becoming increasingly apparent that VEGF is central to
tumour angiogenesis and that high expression of VEGF is associ-
ated with a poor prognosis in some tumours. We have shown
previously that high VEGF mRNA expression is associated with
early recurrence and stage progression to a muscle invasive pheno-
type in superficial bladder cancer (Crew et al, 1997). In this study
VEGF mRNA and protein were measured in 12 samples of normal
bladder and 57 bladder tumours. Since VEGF protein levels were
high in both superficial and muscle invasive tumour phenotypes,
VEGF may still be important in determining the angiogenic
properties within muscle invasive tumours despite the relatively
low VEGF mRNA expression. Nevertheless, our previous hypoth-
esis that superficial and muscle invasive tumours utilize different
angiogenic pathways to stimulate the neovascularization (O’Brien
et al, 1995) is still valid with post-transcriptional mechanisms
regulating VEGF in muscle invasive tumour. Anti-VEGF thera-
peutic strategies have been postulated as new treatment options for
superficial tumours (Crew et al, 1997) and this finding indicates
that they may equally have a role in muscle invasive tumours.
Whilst VEGF mRNA and protein correlated in both superficial
and muscle invasive tumours, protein:mRNA ratio were 17-fold
higher in the latter phenotype compared to normal bladder and
fivefold higher compared to the superficial phenotypes. This
suggests translational regulation. The eIF-4E is implicated in the
control of angiogenesis (Kevil et al, 1995) in part through regula-
tion of VEGF protein translation. Chinese hamster ovary cells
over-expressing eIF-4E have increased secretion of active VEGF
over control cells with no difference in the transcript suggesting
regulation of protein translation (Kevil et al, 1996). The impor-
tance of this factor in tumour biology and angiogenesis is further
supported by increased expression in breast tumours compared to
normal breast and in cell lines (Kerekatte et al, 1995; Anthony
et al, 1996; Scott et al, 1997). Our study strengthens this postulate
with median eIF-4E mRNA expression ninefold greater in muscle
invasive bladder tumours compared to normal bladder and
increasing with worsening tumour stage. The relationship between
eIF-4E expression and tumour aggression may, in part, be medi-
ated through the induction of VEGF and angiogenesis.
Whilst eIF-4E mRNA correlated with VEGF protein:mRNA
ratios in all samples this correlation was poorer in malignant
compared to normal bladder suggesting that factors other than
eIF-4E may be involved in VEGF regulation within tumours. The
regulation of both factors by a third factor, such as the c-myc gene
(Rosenwald et al, 1993) could reduce the correlation and other
members of the initiation complex could be dysregulated besides
eIF-4E (e.g. eIF-4G). Binding of VEGF protein to the extracellular
matrix could account for high VEGF protein:mRNA ratios, as
previously described for other heparin binding angiogenic factor
such as basic FGF (O’Brien et al, 1997). However, this hypothesis
is not supported by our observations as no difference was found in
the distribution of VEGF between membrane and cytosol fractions
for different tumour stages. Furthermore, immunohistochemistry
and in situ hybridization studies (manuscript in preparation) have
indicated that it is the bladder cancer cells that express VEGF at
both the protein and RNA levels respectively, suggesting that
VEGF protein:mRNA ratios are intrinsic to the cancer cells rather
than due to extracellular pools.
The study emphasizes the emerging importance of post-tran-
scriptional mechanisms and eIF-4E in cancer biology and the
pathogenesis of bladder cancer. Stage T1G1 and T1G2 bladder
cancers form a highly heterogeneous group of tumours with a high
risk of recurrence and stage progression carrying with it a poor
prognosis. The prognostic factors presently available in this group
of tumours are inadequate and eIF-4E could offer additional prog-
nostic information. Since the correlation coefficient between
eIF-4E and VEGF was 0.54 this indicates that this factor may give
independent prognostic information compared to VEGF. Such a
prognostic factor (or combination of factors) may be of clinical
value allowing treatment or follow-up of bladder cancer to be
tailored to individual patients.
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